organization · Reporting owner

Philip & Daniele Barach Family Trust

Disclosed activity across 1 company

Tapewire entity: 35883
SEC CIK: 0002107059

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Celularity IncCELU · Entity 7145	10% owner	September 23, 2026	September 25, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Celularity Inc

Report date September 23, 2026 · Filed September 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2028-09-23	Direct	2,000,000	Reported balance After 2026-09-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-23 · Other · Acquired 192,771 · Balance 2,000,000 F1: Represents the amendment and restatement on September 23, 2026 of an existing convertible note of the Issuer in which the applicable conversion price was reduced from $1.66 per share to $1.50 per share and the maturity date was extended from December 31, 2026 to September 23, 2028, as a result of which the number of shares issuable upon conversion of such note was increased from 1,807,229 to 2,000,000. No additional consideration was paid in connection with such amendment and restatement.
Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2028-09-23	Direct	2,140,000	Reported balance After 2026-09-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-23 · Other · Acquired 2,140,000 · Balance 2,140,000 F3: Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the "September 2026 Notes") that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026.
Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2027-09-30	Direct	1,457,765	Reported balance After 2026-09-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-09-23 · Other · Acquired 1,457,765 · Balance 1,457,765 F5: Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the "September 2027 Notes") that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2031-09-23	Direct	1,177,000	Reported balance After 2026-09-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-23 · Other · Acquired 1,177,000 · Balance 1,177,000 F4: Represents shares of Class A Common Stock issuable upon the exercise of 1,177,000 warrants that the Reporting Person obtained from the Issuer in connection with the issuance of the September 2026 Notes. No additional consideration was paid in connection with the issuance of such warrants. F3: Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the "September 2026 Notes") that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2027-09-30	Direct	1,457,765	Reported balance After 2026-09-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-09-23 · Other · Acquired 1,457,765 · Balance 1,457,765 F6: Represents shares of Class A Common Stock issuable upon the exercise of up to 1,457,765 warrants that the Reporting Person has the option to obtain from the Issuer for in connection with the issuance of September 2027 Notes at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid. F5: Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the "September 2027 Notes") that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2031-09-23	Direct	1,258,740	Reported balance Holding disclosure · report date 2026-09-23 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 1,258,740 F2: Represents the amendment and restatement on September 23, 2026 of existing warrants of the Issuer in which exercise price of such warrants was reduced from $2.00 per share to $1.50 per share and the termination date of such warrants was extended to September 23, 2031. No additional consideration was paid in connection with such amendment and restatement.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2030-12-19	Direct	2,448,917	Reported balance Holding disclosure · report date 2026-09-23 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 2,448,917

Filing footnotes · ownership attribution and instrument terms

F1: Represents the amendment and restatement on September 23, 2026 of an existing convertible note of the Issuer in which the applicable conversion price was reduced from $1.66 per share to $1.50 per share and the maturity date was extended from December 31, 2026 to September 23, 2028, as a result of which the number of shares issuable upon conversion of such note was increased from 1,807,229 to 2,000,000. No additional consideration was paid in connection with such amendment and restatement.

F2: Represents the amendment and restatement on September 23, 2026 of existing warrants of the Issuer in which exercise price of such warrants was reduced from $2.00 per share to $1.50 per share and the termination date of such warrants was extended to September 23, 2031. No additional consideration was paid in connection with such amendment and restatement.

F3: Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the "September 2026 Notes") that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026.

F4: Represents shares of Class A Common Stock issuable upon the exercise of 1,177,000 warrants that the Reporting Person obtained from the Issuer in connection with the issuance of the September 2026 Notes. No additional consideration was paid in connection with the issuance of such warrants.

F5: Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the "September 2027 Notes") that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.

F6: Represents shares of Class A Common Stock issuable upon the exercise of up to 1,457,765 warrants that the Reporting Person has the option to obtain from the Issuer for in connection with the issuance of September 2027 Notes at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 23, 2026 Filed Sep 25, 2026 20:59 UTC	Celularity Inc CELU · Entity 7145	OtherWarrants · Derivative	1,457,765	Not disclosed Strike: $2.00	Not disclosed	Disclosure SEC source: 0001104659-26-111028 · tm2626132-4_4seq1.xml · derivative · entry 7 Philip & Daniele Barach Family Trust · CIK 0002107059 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,457,765 Underlying: Class A Common Stock · 1,457,765 shares Expires 2027-09-30 F6 · kind: Represents shares of Class A Common Stock issuable upon the exercise of up to 1,457,765 warrants that the Reporting Person has the option to obtain from the Issuer for in connection with the issuance of September 2027 Notes at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid. F5 · shares: Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the "September 2027 Notes") that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid. F6 · shares: Represents shares of Class A Common Stock issuable upon the exercise of up to 1,457,765 warrants that the Reporting Person has the option to obtain from the Issuer for in connection with the issuance of September 2027 Notes at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid. F5 · price: Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the "September 2027 Notes") that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid. F6 · price: Represents shares of Class A Common Stock issuable upon the exercise of up to 1,457,765 warrants that the Reporting Person has the option to obtain from the Issuer for in connection with the issuance of September 2027 Notes at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid. Read SEC document
September 23, 2026 Filed Sep 25, 2026 20:59 UTC	Celularity Inc CELU · Entity 7145	OtherConvertible Notes · Derivative	1,457,765	Not disclosed Strike: $2.00	Not disclosed	Disclosure SEC source: 0001104659-26-111028 · tm2626132-4_4seq1.xml · derivative · entry 6 Philip & Daniele Barach Family Trust · CIK 0002107059 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,457,765 Underlying: Class A Common Stock · 1,457,765 shares Expires 2027-09-30 F5 · kind: Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the "September 2027 Notes") that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid. F5 · shares: Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the "September 2027 Notes") that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid. F5 · price: Represents shares of Class A Common Stock issuable upon the conversion of up to $2,915,531 in aggregate principal amount of convertible notes (the "September 2027 Notes") that the Reporting Person has the option to purchase from the Issuer at any time until September 30, 2027. Such option is a contractual right granted by the Issuer in connection with the issuance of the September 2026 Notes for, which no additional consideration was paid. Read SEC document
September 23, 2026 Filed Sep 25, 2026 20:59 UTC	Celularity Inc CELU · Entity 7145	OtherWarrants · Derivative	1,177,000	Not disclosed Strike: $1.50	Not disclosed	Disclosure SEC source: 0001104659-26-111028 · tm2626132-4_4seq1.xml · derivative · entry 5 Philip & Daniele Barach Family Trust · CIK 0002107059 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,177,000 Underlying: Class A Common Stock · 1,177,000 shares Expires 2031-09-23 F4 · kind: Represents shares of Class A Common Stock issuable upon the exercise of 1,177,000 warrants that the Reporting Person obtained from the Issuer in connection with the issuance of the September 2026 Notes. No additional consideration was paid in connection with the issuance of such warrants. F3 · price: Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the "September 2026 Notes") that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026. F4 · price: Represents shares of Class A Common Stock issuable upon the exercise of 1,177,000 warrants that the Reporting Person obtained from the Issuer in connection with the issuance of the September 2026 Notes. No additional consideration was paid in connection with the issuance of such warrants. Read SEC document
September 23, 2026 Filed Sep 25, 2026 20:59 UTC	Celularity Inc CELU · Entity 7145	OtherConvertible Notes · Derivative	2,140,000	Not disclosed Strike: $1.50	Not disclosed	Disclosure SEC source: 0001104659-26-111028 · tm2626132-4_4seq1.xml · derivative · entry 4 Philip & Daniele Barach Family Trust · CIK 0002107059 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,140,000 Underlying: Class A Common Stock · 2,140,000 shares Expires 2028-09-23 F3 · kind: Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the "September 2026 Notes") that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026. F3 · shares: Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the "September 2026 Notes") that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026. F3 · price: Represents shares of Class A Common Stock issuable upon the conversion of $3,210,000 in aggregate principal amount of convertible notes (the "September 2026 Notes") that the Reporting Person purchased from the Issuer for such an amount of cash on September 23, 2026. Read SEC document
September 23, 2026 Filed Sep 25, 2026 20:59 UTC	Celularity Inc CELU · Entity 7145	OtherConvertible Notes · Derivative	192,771	Not disclosed Strike: $1.50	Not disclosed	Disclosure SEC source: 0001104659-26-111028 · tm2626132-4_4seq1.xml · derivative · entry 1 Philip & Daniele Barach Family Trust · CIK 0002107059 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Class A Common Stock · 2,000,000 shares Expires 2028-09-23 F1 · kind: Represents the amendment and restatement on September 23, 2026 of an existing convertible note of the Issuer in which the applicable conversion price was reduced from $1.66 per share to $1.50 per share and the maturity date was extended from December 31, 2026 to September 23, 2028, as a result of which the number of shares issuable upon conversion of such note was increased from 1,807,229 to 2,000,000. No additional consideration was paid in connection with such amendment and restatement. F1 · shares: Represents the amendment and restatement on September 23, 2026 of an existing convertible note of the Issuer in which the applicable conversion price was reduced from $1.66 per share to $1.50 per share and the maturity date was extended from December 31, 2026 to September 23, 2028, as a result of which the number of shares issuable upon conversion of such note was increased from 1,807,229 to 2,000,000. No additional consideration was paid in connection with such amendment and restatement. F1 · price: Represents the amendment and restatement on September 23, 2026 of an existing convertible note of the Issuer in which the applicable conversion price was reduced from $1.66 per share to $1.50 per share and the maturity date was extended from December 31, 2026 to September 23, 2028, as a result of which the number of shares issuable upon conversion of such note was increased from 1,807,229 to 2,000,000. No additional consideration was paid in connection with such amendment and restatement. F1 · derivative.underlying_shares: Represents the amendment and restatement on September 23, 2026 of an existing convertible note of the Issuer in which the applicable conversion price was reduced from $1.66 per share to $1.50 per share and the maturity date was extended from December 31, 2026 to September 23, 2028, as a result of which the number of shares issuable upon conversion of such note was increased from 1,807,229 to 2,000,000. No additional consideration was paid in connection with such amendment and restatement. F1 · balance_after: Represents the amendment and restatement on September 23, 2026 of an existing convertible note of the Issuer in which the applicable conversion price was reduced from $1.66 per share to $1.50 per share and the maturity date was extended from December 31, 2026 to September 23, 2028, as a result of which the number of shares issuable upon conversion of such note was increased from 1,807,229 to 2,000,000. No additional consideration was paid in connection with such amendment and restatement. Read SEC document
June 19, 2026 Filed Jun 23, 2026 14:14 UTC	Celularity Inc CELU · Entity 7145	OtherWarrants · Derivative	839,160	Not disclosed Strike: $2.00	Not disclosed	Disclosure SEC source: 0001104659-26-076683 · tm2618448-3_4seq1.xml · derivative · entry 4 Philip & Daniele Barach Family Trust · CIK 0002107059 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 839,160 shares Expires 2030-12-19 F2 · kind: Represented shares of Class A Common Stock issuable upon the exercise of up to 839,160 warrants (the "Warrants") that the Reporting Person had the option to obtain from the Issuer in connection with the purchase by the Reporting Person of the Notes at any time until June 19, 2026. Because the Reporting Person's option to purchase the Notes expired pursuant to its terms on June 19, 2026, the ability to obtain such Warrants also expired on such date. F1 · price: Represented shares of Class A Common Stock issuable upon the conversion of up to $2,000,000 in aggregate principal amount of convertible notes (the "Notes") that the Reporting Person had the option to purchase from the Issuer at any time until June 19, 2026. The option to purchase such Notes expired pursuant to its terms on June 19, 2026, and no consideration was paid in connection with such expiration. F2 · price: Represented shares of Class A Common Stock issuable upon the exercise of up to 839,160 warrants (the "Warrants") that the Reporting Person had the option to obtain from the Issuer in connection with the purchase by the Reporting Person of the Notes at any time until June 19, 2026. Because the Reporting Person's option to purchase the Notes expired pursuant to its terms on June 19, 2026, the ability to obtain such Warrants also expired on such date. Read SEC document
June 19, 2026 Filed Jun 23, 2026 14:14 UTC	Celularity Inc CELU · Entity 7145	OtherConvertible Notes · Derivative	1,204,819	Not disclosed Strike: $1.66	Not disclosed	Disclosure SEC source: 0001104659-26-076683 · tm2618448-3_4seq1.xml · derivative · entry 3 Philip & Daniele Barach Family Trust · CIK 0002107059 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,204,819 shares Expires 2026-12-31 F1 · kind: Represented shares of Class A Common Stock issuable upon the conversion of up to $2,000,000 in aggregate principal amount of convertible notes (the "Notes") that the Reporting Person had the option to purchase from the Issuer at any time until June 19, 2026. The option to purchase such Notes expired pursuant to its terms on June 19, 2026, and no consideration was paid in connection with such expiration. F1 · price: Represented shares of Class A Common Stock issuable upon the conversion of up to $2,000,000 in aggregate principal amount of convertible notes (the "Notes") that the Reporting Person had the option to purchase from the Issuer at any time until June 19, 2026. The option to purchase such Notes expired pursuant to its terms on June 19, 2026, and no consideration was paid in connection with such expiration. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.